Investing.com··Jessica MitacekMerck Bets $6.7B on Cancer Pipeline With Terns Pharmaceutical Acquisition
Merck acquires Terns Pharmaceutical for $6.7B to expand cancer pipeline with oral BCR-ABL1 inhibitor, targeting $70B commercial opportunity by mid-2030s.
MRKABBVLLYTERNacquisitiondividend growth